Neurocrine Biosciences, Inc. (NBIX) Q1 2022 Earnings Results

Neurocrine Biosciences Misses on EPS, Stock Down 0.34%

The earnings report indicates that Neurocrine Biosciences did not meet EPS expectations, which contributed to a slight decline in stock price. Investors may be concerned about the lack of revenue data and guidance, leading to uncertainty about the company's future performance. Management's cautious optimism suggests they are focused on long-term growth despite current challenges.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.30	N/A	-8.26%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism about future prospects. They emphasized the importance of their ongoing projects and the potential for growth.

Management highlighted ongoing investments in research and development.

They expressed confidence in their long-term pipeline despite current challenges.

Neurocrine Biosciences Misses on EPS, Stock Down 0.34%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS, Stock Down 0.34%

Key numbers

Management commentary